# FDA 483 - Blood Bank Of Delmarva, a Division of New York Blood Center, Inc. - February 11, 2020

Source: https://www.globalkeysolutions.net/records/483/blood-bank-of-delmarva-a-division-of-new-york-blood-center-inc/58e74635-f6bc-4510-8716-f59f437dcd7a

> FDA 483 for Blood Bank Of Delmarva, a Division of New York Blood Center, Inc. on February 11, 2020. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Blood Bank Of Delmarva, a Division of New York Blood Center, Inc.
- Inspection Date: 2020-02-11
- Product Type: biologics
- Office Name: Philadelphia District Office
- Summary: An FDA inspection of Blood Bank Of Delmarva, a Division of New York Blood Center, Inc. in Newark, DE, revealed significant issues with donor notification procedures. The firm failed to inform a donor of their deferral status and the reason, specifically after a reactive Anti-HIV-2 EIA test. Additionally, the blood bank did not provide adequate information regarding medical follow-up and counseling to the affected donor.

## Related Officers

- [Amy A. Johnson](https://www.globalkeysolutions.net/people/amy-a-johnson/9933f793-503f-45c5-8837-d46134c20e09)
- [investigator](https://www.globalkeysolutions.net/people/erika-m-wilkerson/cd1c299d-c827-4d52-8e2b-719989da9991)

Company: https://www.globalkeysolutions.net/companies/blood-bank-of-delmarva-a-division-of-new-york-blood-center-inc/184c00da-afce-4c46-bc68-09f608b78abe

Office: https://www.globalkeysolutions.net/offices/philadelphia-district-office/c5ec7398-b3d5-4125-9793-fb7b972578d8